AdvanCell报告,在2025年ESMO会议上提出的第1b阶段试验中,其基于铅的212前列腺癌治疗早期成果大有希望。 AdvanCell reports promising early results from its lead-212-based prostate cancer therapy in a Phase 1b trial, presented at ESMO 2025.

AdvanCell将在2025年ESMO会议上介绍ADVC001第一阶段b试验的早期临床数据,ADVC001是针对前列腺癌的以212为主的铅疗法。 AdvanCell will present early clinical data from its Phase 1b trial of ADVC001, a lead-212-based therapy targeting prostate cancer, at the ESMO 2025 conference. TheraPb试验的结果显示,在前列腺癌高级患者中,安全情况良好,有抗震活动的迹象。 The results, from the TheraPb trial, show a favorable safety profile and signs of anti-tumor activity in patients with advanced prostate cancer. 这标志着首次在一次重大的肿瘤学会议上公开介绍以212为主的PSMA定向治疗的临床数据。 This marks the first public presentation of clinical data from a lead-212-based PSMA-targeted therapy at a major oncology conference. 治疗方法使用α辐射精确地摧毁癌症细胞,同时保留健康组织。 The treatment uses alpha radiation to precisely destroy cancer cells while sparing healthy tissue. 调查结果来自7个剂量组,2025年5月数据被切断。 The findings come from seven dose cohorts, with data cut off in May 2025.